In studies using subcutaneously transplanted tumors, even in tumor models with low PD-L1 expression, it has been shown that blocking PD-L1 expressed on DCs in the lymph nodes promotes the priming of CD8+ T cells and induces significant anti-tumor activity [43]. This evidence concerns the gene CD8A and neoplasm.